The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
126486652 12648665 2 F 2005 20160812 20160812 20160818 EXP JP-SA-2016SA145272 AVENTIS SAMESHIMA S, KOKETSU S, OKUYAMA T, KUBOTA Y, ONO Y, NOIE T, ET AL. ULCERATIVE COLITIS ASSOCIATED WITH NEPHROTIC SYNDROME AFTER TREATMENT WITH MESALAZINE DEVELOPED INTO RECTAL CARCINOMA: A CASE STUDY. WORLD JOURNAL OF SURGICAL ONCOLOGY 2016;14(1):ARTICLE NUMBER 192. DOI: 10.1186/S12957-016-0950-1. ACCESSED: 2016 JUL 22. 22.00 YR A M Y 0.00000 20160818 OT JP JP

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
126486652 12648665 1 SS MESALAZINE MESALAMINE 1 Unknown U UNK 0 2250 MG QD
126486652 12648665 2 SS PREDNISOLONE. PREDNISOLONE 1 Unknown UNK 0 35 MG QD
126486652 12648665 3 SS PREDNISOLONE. PREDNISOLONE 1 Unknown UNK 0 12.5 MG
126486652 12648665 4 PS OXALIPLATIN. OXALIPLATIN 1 Unknown MODIFIED FOLFOX6 UNK 21759
126486652 12648665 5 SS FLUOROURACIL. FLUOROURACIL 1 Unknown MODIFIED FOLFOX6 UNK 0
126486652 12648665 6 SS CYCLOSPORINE. CYCLOSPORINE 1 Unknown UNK 0 250 MG QD
126486652 12648665 7 SS MIZORIBINE MIZORIBINE 1 Unknown UNK 0 150 MG QD
126486652 12648665 8 SS PANITUMUMAB PANITUMUMAB 1 Unknown UNK 0
126486652 12648665 9 SS LEUCOVORIN. LEUCOVORIN 1 Unknown MODIFIED FOLFOX6 UNK 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
126486652 12648665 1 Colitis ulcerative
126486652 12648665 2 Nephrotic syndrome
126486652 12648665 3 Nephrotic syndrome
126486652 12648665 4 Rectal adenocarcinoma
126486652 12648665 5 Rectal adenocarcinoma
126486652 12648665 6 Nephrotic syndrome
126486652 12648665 7 Nephrotic syndrome
126486652 12648665 8 Rectal adenocarcinoma
126486652 12648665 9 Rectal adenocarcinoma

Outcome of event

Event ID CASEID OUTC COD
126486652 12648665 OT
126486652 12648665 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
126486652 12648665 Abdominal distension
126486652 12648665 Abdominal pain
126486652 12648665 Biopsy kidney abnormal
126486652 12648665 Blood albumin decreased
126486652 12648665 Blood creatinine increased
126486652 12648665 Blood urea increased
126486652 12648665 Carbohydrate antigen 19-9 increased
126486652 12648665 Carcinoembryonic antigen increased
126486652 12648665 Drug resistance
126486652 12648665 Dyspnoea
126486652 12648665 Generalised oedema
126486652 12648665 Lymphadenopathy
126486652 12648665 Metastases to lymph nodes
126486652 12648665 Nephrotic syndrome
126486652 12648665 Neuropathy peripheral
126486652 12648665 Protein total decreased
126486652 12648665 Proteinuria
126486652 12648665 Rash
126486652 12648665 Rectal adenocarcinoma
126486652 12648665 Rectal lesion
126486652 12648665 Rectal stenosis
126486652 12648665 Weight increased

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
126486652 12648665 1 2000 0
126486652 12648665 2 2005 0
126486652 12648665 4 2014 0
126486652 12648665 5 2014 0
126486652 12648665 6 2005 0
126486652 12648665 7 2005 0
126486652 12648665 8 2014 0
126486652 12648665 9 2014 0